Viridian Therapeutics, Inc. (VRDN)
NASDAQ: VRDN · Real-Time Price · USD
23.29
+0.45 (1.97%)
Nov 5, 2024, 4:00 PM EST - Market closed
Viridian Therapeutics Revenue
Viridian Therapeutics had revenue of $72.00K in the quarter ending June 30, 2024. This brings the company's revenue in the last twelve months to $288.00K, down -80.41% year-over-year. In the year 2023, Viridian Therapeutics had annual revenue of $314.00K, down -82.28%.
Revenue (ttm)
$288.00K
Revenue Growth
-80.41%
P/S Ratio
n/a
Revenue / Employee
$3,064
Employees
94
Market Cap
1.78B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 314.00K | -1.46M | -82.28% |
Dec 31, 2022 | 1.77M | -1.19M | -40.20% |
Dec 31, 2021 | 2.96M | 1.91M | 182.19% |
Dec 31, 2020 | 1.05M | -3.41M | -76.46% |
Dec 31, 2019 | 4.46M | -3.92M | -46.80% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
National HealthCare | 1.17B |
NovoCure | 577.74M |
AtriCure | 447.57M |
Galapagos NV | 290.09M |
Arvinas | 161.10M |
Tarsus Pharmaceuticals | 83.37M |
Nurix Therapeutics | 56.42M |
Celldex Therapeutics | 8.30M |
VRDN News
- 13 days ago - Viridian Therapeutics' Superior Prospects Make It A Buy - Seeking Alpha
- 6 weeks ago - 3 Small Biotech Stocks With The 'Big Mo' Right Now - Seeking Alpha
- 7 weeks ago - Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock - Business Wire
- 2 months ago - Viridian: Active TED Data Signifies Next Round Of Positive Data On The Way - Seeking Alpha
- 2 months ago - Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock - Business Wire
- 2 months ago - Viridian Therapeutics' eye disorder treatment meets main goal in late-stage study - Reuters
- 2 months ago - Viridian Therapeutics Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease - Business Wire
- 2 months ago - Viridian Therapeutics to Webcast VRDN-001 Phase 3 THRIVE Topline Results on September 10, 2024 - Business Wire